Condition 101 About Neurotoxicity Syndromes

What are the alternative names for Neurotoxicity Syndromes?

  • Toxic encephalopathy

Top Global Doctors For Neurotoxicity Syndromes

GC
Elite
Guido Cavaletti
IT
MC
Elite
Maria A. Cenci
Lund, M, SE
PH
Elite
Philippe P. Huot
Montreal, QC, CA
EB
Elite
Erwan Bezard
Bordeaux, FR
TJ
Elite
Tom H. Johnston
Toronto, ON, CA
MC
Elite
Manolo Carta
Cagliari, IT

Latest Advances On Neurotoxicity Syndromes

  • Condition: B-cell Malignancies, Mantle cell lymphoma, and Multiple Myeloma
  • Journal: Frontiers in immunology
  • Treatment Used: CAR T-Cell Therapy
  • Number of Patients: 0
  • Published —
This article discusses the use of CAR T-cell therapy in the treatment of patients with B-cell malignancies, mantle cell lymphoma, and multiple myeloma.
  • Condition: Neuroleptic Malignant Syndrome (NMS)
  • Journal: The Journal of clinical psychiatry
  • Treatment Used: Long-Acting Injectable Antipsychotic (LAI) vs Oral Antipsychotic (OAP) Treatment
  • Number of Patients: 662
  • Published —
This study evaluated the outcomes of patients with neuroleptic malignant syndrome (life-threatening reaction that can occur in response to neuroleptic or antipsychotic medication; NMS) with long-acting injectable antipsychotic (LAI) versus oral antipsychotic (OAP) treatment.

Clinical Trials For Neurotoxicity Syndromes

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Biological
  • Participants: 25
  • Start Date: February 11, 2021
Phase 2 Pilot Study to Evaluate Efficacy and Safety of Anakinra to Prevent CD19-Targeted CAR-T Cell-Related Cytokine Release Syndrome (CRS) and Neurotoxicity in Patients With B Cell Lymphoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 20
  • Start Date: October 5, 2020
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity